The Hypertrophic Scars drugs in development market research report provides comprehensive information on the therapeutics under development for Hypertrophic Scars, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hypertrophic Scars. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hypertrophic Scars and features dormant and discontinued products.
GlobalData tracks 14 drugs in development for Hypertrophic Scars by 14 companies/universities/institutes. The top development phase for Hypertrophic Scars is preclinical with six drugs in that stage. The Hypertrophic Scars pipeline has 14 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hypertrophic Scars pipeline products market are: Shanghai Ark Biopharmaceutical, Scarless Laboratories and AMD Therapeutics.
The key targets in the Hypertrophic Scars pipeline products market include Epithelial Discoidin Domain Containing Receptor 1 (CD167 Antigen Like Family Member A or Mammary Carcinoma Kinase 10 or Protein Tyrosine Kinase 3A or Protein Tyrosine Kinase RTK 6 or Tyrosine Protein Kinase CAK or CD167a or DDR1 or EC 2.7.10.1), Connective Tissue Growth Factor (CCN Family Member 2 or Hypertrophic Chondrocyte Specific Protein 24 or Insulin Like Growth Factor Binding Protein 8 or IGFBP8 or CTGF), and C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4).
The key mechanisms of action in the Hypertrophic Scars pipeline product include Thymidylate Synthase (TYMS or EC 2.1.1.45) Inhibitor with one drug in Preclinical. The Hypertrophic Scars pipeline products include eight routes of administration with the top ROA being Topical and six key molecule types in the Hypertrophic Scars pipeline products market including Small Molecule, and Antisense RNAi Oligonucleotide.
Hypertrophic Scars overview
A hypertrophic scar is a cutaneous condition characterized by deposits of excessive amounts of collagen which gives rise to a raised scar. It occurs when the body overproduces collagen, which causes the scar to be raised above the surrounding skin. Hypertrophic scars take the form of a red raised lump on the skin for lighter pigmented skin and the form of dark brown for darker pigmented skin. They usually occur within 4 to 8 weeks following wound infection or wound closure with excess tension and/or other traumatic skin injuries.
For a complete picture of Hypertrophic Scars’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
